Statins and the primary prevention of cardiovascular events

Current Atherosclerosis Reports

Volumn 8, Issue 5, 2006, Pages 390-396

  Clearfield, Michael ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENTIATION; EPIDEMIOLOGICAL DATA; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; METABOLIC SYNDROME X; OBESITY; PATIENT CODING; PATIENT SELECTION; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; UNITED STATES;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; TREATMENT OUTCOME;

EID: 33748433653     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0036-6     Document Type: Review

References (36)

1. Murray CJ, Lopez AD, (eds.): The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Boston: Harvard School of Public Health; 1996.
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
3. Grundy SM, Cleeman JI, Bairey CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-229.
4. Shepherd J, Cobbe SM, Ford I, et al., for The West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
5. Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998, 279:1615-1622.
6. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomized placebo controlled trial. Lancet 2002, 360:7-22.
7. Prosper Study Group: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized placebo-controlled trial. Lancet 2002, 360:1623-1630.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002, 288:2998-3007.
9. Sever PS, Dalhof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
10. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomized placebo-controlled trial. Lancet 2004, 364:685-696.
11. Cholesterol Treatment Trialists Collaborators: Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005, 366:1267-1278.
12. Clearfield M, Downs JR, Lee M, et al.: Implications from the Air Force/ Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III Guidelines. Am J Cardiol 2005, 96:1674-1680.
13. O'Keefe HH, Cordain L, Harris WH, et al.: Optimal low density lipoprotein is 50 to 70 mg/dl. J Am Coll Cardiol 2004, 43:2142-2146.
14. Ridker PM: Rosuvastatin in primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high sensitivity c-reactive protein: rationale and design of the JUPITER Trial. Circulation 2003, 108:2292-2297.
15. Ridker PM, Rifai N, Clearfield M, et al.: Measurement of C-Reactive protein for targeting of statin therapy in the primary prevention of acute coronary events. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. N Engl J Med 2001, 344:1959-1965.
16. Ford ES: Risks for all cause mortality, cardiovascular disease and diabetes associated with the metabolic syndrome. Diabetes Care 2005, 28:1769-1778.
17. Girman CJ, Rhodes T, Mercuri M, et al.: The metabolic syndrome and risk of major coronary events in the 4S and AFCAPS/TexCAPS study. Am J Cardiol 2004, 93:136-141.
18. Sattar N, Gaw A, Scherbakova O, et al.: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414-419.
19. Eberly LE, Prineas R, Cohen JD, et al.: Metabolic syndrome; risk factor distribution and 19 year mortality in the Multiple Risk Factor Intervention Trial. Diabetes Care 2006, 29:123-130.
20. Lloyd-Jones DM, Nam BH, D'Agostino RB, et al.: Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA 2004, 292:2204-2211.
21. Reinhard W, Holmer SR, Fischer M, et al.: Association of the metabolic syndrome with early coronary disease in families with frequent myocardial infarction. Am J Cardiol 2006, 97:964-967.
22. Ridker PM, Buring JE, Cook NR, et al.: C-reactive protein, the metabolic syndrome and risk incident cardiovascular events. Circulation 2003, 107:391-397.
23. Malik S, Wong ND, Franklin S, et al.: Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes and elevated C-reactive protein. Diabetes Care 2005, 28:690-693.
24. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004, 109:282-2825.
25. Sdringola S, Nakagawa K, Nakagawa Y, et al.: Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual care cholesterol lowering drugs in coronary artery disease. J Am Coll Cardiol 2003, 41:263-272.
26. Muhlstein JB: Post-hospiralization management of high risk coronary patients. Am J Cardiol 2000, 85:13B-20B.
27. Mukherjee D, Fang J, Chetcuti S, et al.: Impact of combination evidence-based medical therapy in patients with acute coronary syndrome Circulation 2004, 109:745-749.28.
28. Hennekens CH, Sacks FM, Tonkin A, et al.: Additive benefits of pravastati and aspirin to decrease risks of cardivascular disease. Arch Intern Med 2004, 164:40-44.
29. Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid lowering in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
30. Brown G, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
31. Grover SA, Pacquet S, Levinton C, et al.: Estimating the benefits of modifying risk factors of cardiovascular disease. Arch Intern Med 1998, 158:655-662.
32. Go AS, Iribarren C, Chandra M, et al.: Statin and B-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med 2006, 144:229-238.
33. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
34. Gaede P: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999, 353:617-622.
35. Wong ND, Pio JR, Franklin SS, et al.: Preventing coronary events by optimal control of blood pressure, and lipids in patients with the metabolic syndrome. Am J Cardiol 2003, 91:1421-1426.
36. Wald NJ, Law MR: A stategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 28:1419-1423.